Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling

被引：139

作者：

Chen, Edwin ^{[1
,2
]}

Beer, Philip A. ^{[1
,2
,3
]}

Godfrey, Anna L. ^{[1
,2
,3
]}

Ortmann, Christina A. ^{[1
,2
,3
]}

Li, Juan ^{[1
,2
]}

Costa-Pereira, Ana P. ^{[4
]}

Ingle, Catherine E. ^{[5
]}

Dermitzakis, Emmanouil T. ^{[5
]}

Campbell, Peter J. ^{[5
]}

Green, Anthony R. ^{[1
,2
,3
]}

机构：

[1] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England

[2] Univ Cambridge, Dept Haematol, Cambridge CB2 0XY, England

[3] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 0XY, England

[4] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Surg & Canc, London W12 0NN, England

[5] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England

来源：

CANCER CELL | 2010年 / 18卷 / 05期

关键词：

HEMATOPOIETIC STEM-CELLS; V617F MUTATION OCCURS; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; GENE-EXPRESSION; ESSENTIAL THROMBOCYTHEMIA; CYTOKINE RECEPTOR; MYELOPROLIFERATIVE DISORDERS; ACTIVATION; PHOSPHORYLATION;

D O I：

10.1016/j.ccr.2010.10.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The JAK2V617F mutation is associated with distinct myeloproliferative neoplasms, including polycythemia vera (PV) and essential thrombocythemia (ET), but it remains unclear how it generates disparate disorders. By comparing clonally-derived mutant and wild-type cells from individual patients, we demonstrate that the transcriptional consequences of JAK2V617F are subtle, and that JAK2V617F-heterozygous erythroid cells from ET and PV patients exhibit differential interferon signaling and STAT1 phosphorylation. Increased STAT1 activity in normal CD34-positive progenitors produces an ET-like phenotype, whereas downregulation of STAT1 activity in JAK2V617F-heterozygous ET progenitors produces a PV-like phenotype. Our results illustrate the power of clonal analysis, indicate that the consequences of JAK2V617F reflect a balance between STAT5 and STAT1 activation and are relevant for other neoplasms associated with signaling pathway mutations.

引用

页码：524 / 535

页数：12

共 62 条

[1] POLYCYTHEMIA-VERA - STEM-CELL AND PROBABLE CLONAL ORIGIN OF DISEASE [J].

ADAMSON, JW ;

FIALKOW, PJ ;

MURPHY, S ;

PRCHAL, JF ;

STEINMANN, L .

NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (17) :913-916

[2] Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease [J].

Akada, Hajime ;

Yan, Dongqing ;

Zou, Haiying ;

Fiering, Steven ;

Hutchison, Robert E. ;

Mohi, M. Golam .

BLOOD, 2010, 115 (17) :3589-3597

[3] Quiescent haematopoietic stem cells are activated by IFN-γ in response to chronic infection [J].

Baldridge, Megan T. ;

King, Katherine Y. ;

Boles, Nathan C. ;

Weksberg, David C. ;

Goodell, Margaret A. .

NATURE, 2010, 465 (7299) :793-U9

[4] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[5] Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F [J].

Berkofsky-Fessler, Windy ;

Buzzai, Monica ;

Kim, Marianne K-H. ;

Fruchtman, Steven ;

Najfeld, Vesna ;

Min, Dong-Joon ;

Costa, Fabricio F. ;

Bischof, Jared M. ;

Soares, Marcelo B. ;

McConnell, Melanie Jane ;

Zhang, Weijia ;

Levine, Ross ;

Gilliland, D. Gary ;

Calogero, Raffaele ;

Licht, Jonathan D. .

CLINICAL CANCER RESEARCH, 2010, 16 (17) :4339-4352

[6] Genetical Genomics: Spotlight on QTL Hotspots [J].

Breitling, Rainer ;

Li, Yang ;

Tesson, Bruno M. ;

Fu, Jingyuan ;

Wu, Chunlei ;

Wiltshire, Tim ;

Gerrits, Alice ;

Bystrykh, Leonid V. ;

de Haan, Gerald ;

Su, Andrew I. ;

Jansen, Ritsert C. .

PLOS GENETICS, 2008, 4 (10)

[7] Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study [J].

Campbell, PJ ;

Scott, LM ;

Buck, G ;

Wheatley, K ;

East, CL ;

Marsden, JT ;

Duffy, A ;

Boyd, EM ;

Bench, AJ ;

Scott, MA ;

Vassiliou, GS ;

Milligan, DW ;

Smith, SR ;

Erber, WN ;

Bareford, D ;

Wilkins, BS ;

Reilly, JT ;

Harrison, CN ;

Green, AR .

LANCET, 2005, 366 (9501) :1945-1953

[8] VEGFR1-activity-independent metastasis formation [J].

Dawson, Michelle R. ;

Duda, Dan G. ;

Fukumura, Dai ;

Jain, Rakesh K. .

NATURE, 2009, 461 (7262) :E4-E5

[9] Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis [J].

Delhommeau, Francois ;

Dupont, Sabrina ;

Tonetti, Carole ;

Masse, Aline ;

Godin, Isabelle ;

Le Couedic, Jean-Pierre ;

Debili, Najet ;

Saulnier, Patrick ;

Casadevall, Nicole ;

Vainchenker, William ;

Giraudier, Stephane .

BLOOD, 2007, 109 (01) :71-77

[10] The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera [J].

Dupont, Sabrina ;

Masse, Aline ;

James, Chloe ;

Teyssandier, Irene ;

Lecluse, Yann ;

Larbret, Frederic ;

Ugo, Valerie ;

Saulnier, Patrick ;

Koscielny, Serge ;

Le Couedic, Jean Pierre ;

Casadevall, Nicole ;

Vainchenker, William ;

Delhommeau, Francois .

BLOOD, 2007, 110 (03) :1013-1021

← 1 2 3 4 5 6 7 →